Mosunetuzumab is in clinical development for the treatment of relapsed or refractory follicular lymphoma (FL). FL is a type of blood cancer originating in the lymph nodes of the immune system, and it is the most common type of low-grade Non-Hodgkin’s Lymphoma in the UK. A relapsed or refractory cancer is one that has come back after a successful treatment regimen or has not responded to a previous regimen, meaning a new interventional approach is required in both cases.
Mosunetuzumab (subcutaneous injection) for treating relapsed or refractory follicular lymphoma
Mosunetuzumab is in clinical development for the treatment of relapsed or refractory follicular lymphoma (FL). FL is a type of blood cancer originating in the lymph nodes of the immune system, and it is the most common type of low-grade Non-Hodgkin’s Lymphoma in the UK. A relapsed or refractory cancer is one that has come back after a successful treatment regimen or has not responded to a previous regimen, meaning a new interventional approach is required in both cases. Although the survival rates for FL are relatively high compared to some other cancers, the disease can cause a range of issues that decrease patient quality of life. There are currently limited options for the second-line or greater treatments required for relapsed and refractory patients with FL. This indicates that there remains an unmet need to treat relapsed or refectory FL.